TY - JOUR
T1 - Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic Esophagitis
AU - Schoepfer, Alain M.
AU - Schürmann, Camilla
AU - Trelle, Sven
AU - Zwahlen, Marcel
AU - Ma, Christopher
AU - Chehade, Mirna
AU - Dellon, Evan S.
AU - Jairath, Vipul
AU - Feagan, Brian G.
AU - Bredenoord, Albert J.
AU - Biedermann, Luc
AU - Greuter, Thomas
AU - Schreiner, Philipp
AU - Straumann, Alex
AU - Safroneeva, Ekaterina
N1 - Funding Information:
A.M. Schoepfer received (i) consulting fees and/or speaker fees and/or research grants from Adare Pharmaceuticals, Inc., AstraZeneca, AG, Switzerland, Aptalis Pharma, Inc., Celgene Corp., Dr. Falk Pharma, GmbH, Germany, Glaxo Smith Kline, AG, Nestlé S. A., Switzerland, Novartis, AG, Switzerland, Receptos, Inc., and Regeneron Pharmaceuticals, Inc.; C. Ma has (i) received consulting fees from AVIR Pharma Inc. and Alimentiv (formerly Robarts Clinical Trials Inc.); M. Chehade received (i) research funding from Regeneron, Allakos, Shire, AstraZeneca, Danone; consulting fees from Regeneron, Allakos, Adare, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb; E.S. Dellon (i) received research funding from: Adare/Ellodi, Allakos, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Shire/Takeda; consulting fees from: Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Parexel, Regeneron, Alimentiv Inc., Salix, Sanofi, Shire/Takeda; and educational grants from: Allakos, Banner, Holoclara; Jairath reports (i) consulting fees from Alimentiv Inc. (formerly Robarts Clinicaly Trials, Inc.); B.G. Feagan reports (i) consulting fees from Allakos, Alimentiv Inc. (formerly Robarts Clinical Trials, Inc.), Sanofi, Bristol Myers Squibb; L. Biedermann reports (i) personal fees from Vifor, Falk Pharma, Esocap, Calypso; T. Greuter reports (i) consulting contracts with Falk Pharma GmbH and Sanofi-Aventis, and research grant from Novartis; P. Schreiner reports (i) consulting fees from Pfizer, Takeda and Janssen-Cilag; A. Straumann reports (i) personal fees from Allakos, AstraZeneca, Calypso, EsoCap, Falk Pharma, Gossamer, Nutricia, Pfizer, Receptos-Celgene, Regeneron-Sanofi, Roche-Genentec, Shire, Tillotts; E. Safroneeva (i) received consulting fees from AVIR Pharma Inc., Aptalis Pharma, Inc., Celgene Corp., Novartis, AG, and Regeneron Pharmaceuticals Inc. The rest of the authors have no conflicts of interest to declare.
Funding Information:
Work supported by grants from the Swiss National Science Foundation (32473B_160115 to A.M.S. and 32473B_185008 to E.S.).
Publisher Copyright:
© 2021 S. Karger AG, Basel.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Background: Over the last 20 years, diverse outcome measures have been used to evaluate the effectiveness of therapies for eosinophilic esophagitis (EoE). This systematic review aims to identify the readouts used in observational studies of topical corticosteroids, diet, and dilation in adult EoE patients. Methods: We searched MEDLINE and Embase for prospective and retrospective studies (cohorts/case series, randomized open-label, and case-control) evaluating the use of diets, dilation, and topical corticosteroids in adults with EoE. Two authors independently assessed the articles and extracted information about histologic, endoscopic, and patient-reported outcomes and tools used to assess treatment effects. Results: We included 69 studies that met inclusion criteria. EoE-associated endoscopic findings (assessed either as absence/presence or using Endoscopic Reference Score) were evaluated in 24/35, 11/17, and 9/17 studies of topical corticosteroids, diet, and dilation, respectively. Esophageal eosinophil density was recorded in 32/35, 17/17, and 11/17 studies of topical corticosteroids, diet, and dilation, respectively. Patient-reported outcomes were not uniformly used (only in 14, 8, and 3 studies of topical corticosteroids, diet, and dilation, respectively), and most tools were not validated for use in adults with EoE. Conclusions: Despite the lack of an agreed set of core outcomes that should be recorded and reported in studies in adult EoE patients, endoscopic EoE-associated findings and esophageal eosinophil density are commonly used to assess disease activity in observational studies. Standardization of outcomes and data supporting the use of outcomes are needed to facilitate interpretation of evidence, its synthesis, and comparisons of interventions in meta-analyses of therapeutic trials in adults with EoE.
AB - Background: Over the last 20 years, diverse outcome measures have been used to evaluate the effectiveness of therapies for eosinophilic esophagitis (EoE). This systematic review aims to identify the readouts used in observational studies of topical corticosteroids, diet, and dilation in adult EoE patients. Methods: We searched MEDLINE and Embase for prospective and retrospective studies (cohorts/case series, randomized open-label, and case-control) evaluating the use of diets, dilation, and topical corticosteroids in adults with EoE. Two authors independently assessed the articles and extracted information about histologic, endoscopic, and patient-reported outcomes and tools used to assess treatment effects. Results: We included 69 studies that met inclusion criteria. EoE-associated endoscopic findings (assessed either as absence/presence or using Endoscopic Reference Score) were evaluated in 24/35, 11/17, and 9/17 studies of topical corticosteroids, diet, and dilation, respectively. Esophageal eosinophil density was recorded in 32/35, 17/17, and 11/17 studies of topical corticosteroids, diet, and dilation, respectively. Patient-reported outcomes were not uniformly used (only in 14, 8, and 3 studies of topical corticosteroids, diet, and dilation, respectively), and most tools were not validated for use in adults with EoE. Conclusions: Despite the lack of an agreed set of core outcomes that should be recorded and reported in studies in adult EoE patients, endoscopic EoE-associated findings and esophageal eosinophil density are commonly used to assess disease activity in observational studies. Standardization of outcomes and data supporting the use of outcomes are needed to facilitate interpretation of evidence, its synthesis, and comparisons of interventions in meta-analyses of therapeutic trials in adults with EoE.
KW - Corticosteroids
KW - Diet
KW - Dilation
KW - Eosinophilic esophagitis
KW - Outcomes
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85111053704&partnerID=8YFLogxK
U2 - 10.1159/000516898
DO - 10.1159/000516898
M3 - Article
AN - SCOPUS:85111053704
SN - 1018-2438
VL - 182
SP - 1169
EP - 1193
JO - International Archives of Allergy and Immunology
JF - International Archives of Allergy and Immunology
IS - 12
ER -